| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/30/2006 | CA2580606A1 Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 03/30/2006 | CA2580533A1 Methods of treating disorders having a component of mercury toxicity |
| 03/30/2006 | CA2580397A1 Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat |
| 03/30/2006 | CA2580265A1 Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof |
| 03/30/2006 | CA2580250A1 Loxapine analogs and methods of use thereof |
| 03/30/2006 | CA2580229A1 Dna-pk inhibitors |
| 03/30/2006 | CA2580219A1 Polymorphs of the cysteine protease inhibitor n-(1-cyanocyclopropyl)-3-cyclopropylmethanesulfonyl-2(r)-(2,2,2-trifluoro-1(s)-(4-fluorophenyl) ethylamino)propionamide |
| 03/30/2006 | CA2580215A1 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/30/2006 | CA2580203A1 Tricycles, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | CA2580198A1 Novel phthalazinone derivatives as aurora-a kinase inhibitors |
| 03/30/2006 | CA2580147A1 Composition for prevention or alleviation of pigmentation |
| 03/30/2006 | CA2579907A1 Carbo- and hetero-cyclic antibiotics and use thereof |
| 03/30/2006 | CA2579820A1 Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity |
| 03/30/2006 | CA2579687A1 Salts of 5-azacytidine |
| 03/30/2006 | CA2579412A1 Indole derivatives, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | CA2579408A1 1,2,3 -triazole derivatives as receptor tyrosine kinase inhibitors |
| 03/30/2006 | CA2579406A1 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors |
| 03/30/2006 | CA2579169A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 03/30/2006 | CA2578953A1 Memantine for the treatment of childhood behavioral disorders |
| 03/30/2006 | CA2578824A1 Crystalline form 2 of atrasentan hydrochloride |
| 03/30/2006 | CA2578121A1 Use of metronidazole combined with azelaic acid for the treatment of rosacea |
| 03/30/2006 | CA2577818A1 New heterocyclic amides |
| 03/30/2006 | CA2577799A1 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors |
| 03/30/2006 | CA2577772A1 Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases |
| 03/30/2006 | CA2577413A1 Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
| 03/30/2006 | CA2576982A1 Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof |
| 03/30/2006 | CA2576614A1 2-substituted estrogen sulphamates for inhibition of steroid sulphatase |
| 03/30/2006 | CA2575790A1 The use of a modafinil compound for the treatment of problem gambling |
| 03/30/2006 | CA2575269A1 Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
| 03/30/2006 | CA2575265A1 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders |
| 03/30/2006 | CA2574220A1 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
| 03/30/2006 | CA2572154A1 Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| 03/30/2006 | CA2543757A1 Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives |
| 03/29/2006 | EP1641262A1 Circuit for processing video signal containing information such as closed caption |
| 03/29/2006 | EP1640799A1 Laser projector |
| 03/29/2006 | EP1640452A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 03/29/2006 | EP1640449A1 Cell differentiation inhibiting agent, cell culture method using the same, culture medium and cultured cell line |
| 03/29/2006 | EP1640383A1 Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1640374A1 Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| 03/29/2006 | EP1640359A2 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides |
| 03/29/2006 | EP1640025A1 Composition for external use |
| 03/29/2006 | EP1640022A1 Menthol-containing preparation |
| 03/29/2006 | EP1640011A1 Novel complexes of fatty acid esters of polyhydroxylalkanes and pyridine carboxy derivates |
| 03/29/2006 | EP1640010A1 Agent inducing increase in bone mass |
| 03/29/2006 | EP1640009A1 Estrogenic compounds as antimitotic agents |
| 03/29/2006 | EP1640008A1 A stabilized aqueous (6S)-folinic acid preparation for injection |
| 03/29/2006 | EP1640007A1 Antiepileptic agent |
| 03/29/2006 | EP1640006A1 Sustained drug-relase particles and process for producing the same |
| 03/29/2006 | EP1640005A2 Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin B6 |
| 03/29/2006 | EP1640004A1 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/29/2006 | EP1640003A2 Compositions comprising a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 receptor antagonist |
| 03/29/2006 | EP1640002A1 Indazole derivatives for inhibition of angiogenesis |
| 03/29/2006 | EP1640001A1 Composition against cardiovascular diseases |
| 03/29/2006 | EP1640000A2 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 03/29/2006 | EP1639997A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639996A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639994A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids |
| 03/29/2006 | EP1639992A2 Process for preparing of N-branched-chain alkyl-substituted mercapto acetamides |
| 03/29/2006 | EP1639991A2 Skin and tissue care and/or treatment composition |
| 03/29/2006 | EP1639971A1 Skin protecting compositions |
| 03/29/2006 | EP1639903A1 Composition and foods for lowering glycemic index |
| 03/29/2006 | EP1639902A1 Movement physiology improver |
| 03/29/2006 | EP1639141A2 Methods for treating lentivirus infections |
| 03/29/2006 | EP1639131A1 Method for investigating cytosine methylation in dna sequences by means of triplex-forming oligomers |
| 03/29/2006 | EP1639121A2 Synthesis of beta -l-2-deoxy nucleosides |
| 03/29/2006 | EP1638978A2 7-substituted camptothecin and camptothecin analogs and methods for preparing same |
| 03/29/2006 | EP1638977A1 Salinosporamides and methods for use thereof |
| 03/29/2006 | EP1638972A2 Novel crystalline forms of valacyclovir hydrochloride |
| 03/29/2006 | EP1638969A2 Cgrp receptor antagonists |
| 03/29/2006 | EP1638968A1 Hexahydropyridoisoqinolines as dpp-iv inhibitors |
| 03/29/2006 | EP1638967A2 Cycloalkanepyrrolopyridines as dp receptor antagonists |
| 03/29/2006 | EP1638966A2 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO ¬3,4-d| PYRIMIDINE AND PYRROLO ¬2,3-d| PYRIMIDINE AND USES THEREOF |
| 03/29/2006 | EP1638963A1 N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
| 03/29/2006 | EP1638959A1 5ht -4 -antagonistic 4-(aminomethyl)-piperidine benzamides |
| 03/29/2006 | EP1638950A2 Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/29/2006 | EP1638947A2 Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1 |
| 03/29/2006 | EP1638943A2 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
| 03/29/2006 | EP1638941A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| 03/29/2006 | EP1638938A2 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| 03/29/2006 | EP1638936A1 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| 03/29/2006 | EP1638931A2 Method of targeting a therapeutic agent |
| 03/29/2006 | EP1638919A1 Sphingolipids polyalkylamines conjugates |
| 03/29/2006 | EP1638625A2 Organosulphur prodrugs for the prevention and treatment of infectious diseases and pathologenic immune system response |
| 03/29/2006 | EP1638624A2 Medical devices and methods for regulating the tissue response to vascular closure devices |
| 03/29/2006 | EP1638613A1 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 03/29/2006 | EP1638611A1 Sphingolipids polyalkylamine conjugates for use in transfection |
| 03/29/2006 | EP1638610A1 Sphingoid polyalkylamine conjugates for vaccination |
| 03/29/2006 | EP1638607A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| 03/29/2006 | EP1638591A1 Class iii slrp agonists for the reduction of blood vessel formation |
| 03/29/2006 | EP1638589A2 Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| 03/29/2006 | EP1638586A2 A synergistic composition for the treatment of diabetes mellitus |
| 03/29/2006 | EP1638582A1 Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas |
| 03/29/2006 | EP1638581A2 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 03/29/2006 | EP1638580A2 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 03/29/2006 | EP1638579A2 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury |
| 03/29/2006 | EP1638578A2 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 03/29/2006 | EP1638577A1 Pharmaceutical preparation for treating tropical parasitic diseases containing diaminazen-diaceturate and/or pentamidine |
| 03/29/2006 | EP1638576A1 Combination of acetylsalicylic acid and alpha-glucosidase inhibitors |
| 03/29/2006 | EP1638575A2 Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |